Trials / Completed
CompletedNCT00883064
To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions
Randomized, 2-Way Crossover, Bioequivalence Study of Eon Labs Manufacturing Inc. (USA) and Zeneca (USA) (Zestril) 40 mg Lisinopril Tablet Administered as a 1 x 40 mg Tablet in Health Adult Males Under Fasting Conditions.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- Male
- Age
- 18 Years – 54 Years
- Healthy volunteers
- Accepted
Summary
To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA) | |
| DRUG | Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA) |
Timeline
- Start date
- 2000-03-01
- Primary completion
- 2000-04-01
- Completion
- 2000-04-01
- First posted
- 2009-04-17
- Last updated
- 2017-03-29
Source: ClinicalTrials.gov record NCT00883064. Inclusion in this directory is not an endorsement.